NeuroSense Therapeutics will present updates on its lead ALS drug candidate, PrimeC, at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will cover recent clinical and regulatory progress, including preparations for the Phase 3 PARAGON trial and strategies for potential U.S. approval. PrimeC is an oral therapy targeting multiple pathways in ALS, with positive Phase 2b results showing slowed disease progression. Management will also hold one-on-one meetings with investors during the event.
RH is set to report Q2 2026 earnings facing challenges from a weak housing market and international expansion expenses. Analysts expect earnings per share to fall significantly to between $0.38 and $0.46, down from $2.93 last year, despite a slight r...
Chewy reported Q2 results largely in line with expectations, with net sales up 7.3% to $3.33 billion and adjusted earnings matching forecasts at $0.36 per share. However, shares fell 10.8% due to concerns about slowing organic growth, cautious consum...
Macy's reported Q1 earnings per share of $0.40, exceeding the $0.37 estimate, with revenue of $4.87 billion beating expectations. Growth was driven by strong sales in Bloomingdale's, Bluemercury, and Macy's stores. The company raised its full-year ne...
Tyson Foods faces operational challenges, especially in its beef segment, leading Piper Sandler to cut its price target from $78 to $66. The company lowered its 2026 revenue growth forecast to 1.5%-2% and expects a beef segment operating loss between...
Descartes Systems Group is set to release its Q2 2027 earnings with analysts expecting $0.57 EPS and $197.54 million revenue. The company recently acquired Extensiv for $120 million, enhancing its warehouse and fulfillment solutions for e-commerce an...
